EWA
CORT icon

EverSource Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

EverSource Wealth Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Buy
1,687
+1,347
+396% +$81.3K ﹤0.01% 1183
2026
Q1 		$13.7K Sell
340
-2,091
-86% -$78.2K ﹤0.01% 2745
2025
Q4 		$84.6K Sell
2,431
-147
-6% -$11.5K ﹤0.01% 1401
2025
Q3 		$214K Buy
2,578
+1,137
+79% +$82.3K 0.01% 871
2025
Q2 		$106K Buy
1,441
+1,055
+273% +$76.5K ﹤0.01% 1171
2025
Q1 		$44.1K Buy
386
+289
+298% +$17.6K ﹤0.01% 1294
2024
Q4 		$4.89K Buy
97
+52
+116% +$2.73K ﹤0.01% 2362
2024
Q3 		$2.08K Hold
45
– – ﹤0.01% 2536
2024
Q2 		$1.74K Buy
45
+7
+18% +$192 ﹤0.01% 2596
2024
Q1 		$886 Buy
38
+6
+19% +$142 ﹤0.01% 2621
2023
Q4 		$1.04K Hold
32
– – ﹤0.01% 2394
2023
Q3 		$872 Buy
+32
New +$926 ﹤0.01% 2283
2022
Q4 		– Sell
-59
Closed -$2K – 2330
2022
Q3 		$2K Buy
+59
New +$1.58K ﹤0.01% 1641

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's CORT Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Corcept Therapeutics (CORT) stake by 396% in Q2 2026, buying an estimated $81.3K and bringing the position to 1,687 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

EverSource Wealth Advisors first reported a position in CORT in Q3 2022 and has held it in 13 quarters since. The position peaked at $214K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • EverSource Wealth Advisors held 1,687 shares of Corcept Therapeutics worth $147K as of Q2 2026.
  • EverSource Wealth Advisors bought 1,347 Corcept Therapeutics shares in Q2 2026, an estimated $81.3K.
  • Corcept Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1183 holding.
  • EverSource Wealth Advisors first reported a position in Corcept Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • EverSource Wealth Advisors's Corcept Therapeutics position peaked at $214K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.